Regional haemodynamic effects of cyclosporine A, tacrolimus and sirolimus in conscious rats

British Journal of Pharmacology

Volumn 141, Issue 4, 2004, Pages 634-643

  Gardiner, S M ^a   March, J E ^a   Kemp, P A ^a   Fallgren, B ^b   Bennett, T ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b R and D Consultancy   (Sweden)

Author keywords

Cyclosporine A; Haemodynamics; Sirolimus; Tacrolimus

Indexed keywords

3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATIPAMEZOLE; CALCINEURIN; CALCINEURIN INHIBITOR; CYCLOSPORIN A; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; IMMUNOSUPPRESSIVE AGENT; LOSARTAN; MEDETOMIDINE; NALBUPHINE; PHENTOLAMINE; PHENTOLAMINE MESYLATE; PROPRANOLOL; RAPAMYCIN; TACROLIMUS;

ADRENERGIC SYSTEM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; HEMODYNAMIC MONITORING; HYPERTENSION; IMMUNOMODULATION; INHIBITION KINETICS; KIDNEY BLOOD FLOW; MALE; MESENTERIC BLOOD VESSEL OCCLUSION; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RAT; TACHYCARDIA; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CYCLOSPORINE; DRUG INTERACTIONS; HEART RATE; HEMODYNAMIC PROCESSES; IMMUNOSUPPRESSIVE AGENTS; INDANS; INFUSIONS, INTRAVENOUS; LOSARTAN; MALE; PHENTOLAMINE; PROPRANOLOL; RATS; RATS, SPRAGUE-DAWLEY; REGIONAL BLOOD FLOW; RENAL CIRCULATION; SIROLIMUS; TACROLIMUS;

EID: 1842506212     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705659     Document Type: Article

References (52)

1. ABRAHAM, J.S., BENTLEY, F.R., GARRISON, N.R. & CRYER, H.M. (1991). The influence of the cyclosporine vehicle, cremophor EL, on renal microvascular blood flow in the rat. Transplantation. 52, 101-105.
2. BENIGNI, A., MORIGI, M., PERICO, N., ZOJA, C., AMUSCHATEGUI, C.S., PICCINELLI, A., DONADELLI, R. & REMUZZI, G. (1992). The acute effect of FK 506 and cyclosporine on endothelial cell function and renal vascular resistance. Transplantation. 54, 775-778.
3. BENNETT, T. & GARDINER, S.M. (2003). Fostering orphan receptors: an indispensable role for integrative, in vivo, haemodynamic studies. Curr. Opin. Pharmacol., 3, 1-6.
4. BENNETT, T., GARDINER, S.M., KEMP, P.A., MARCH, J.E. & FALLGREN, B. (2004). Regional haemodynamic effects of cyclosporine A (CsA) in conscious rats. Br. J. Pharmacol., (in press).
5. BOREL, J.F. (1989). Pharmacology of cyclosproine (Sandimmune) IV pharmacological properties in vivo. Pharmacol. Rev., 41, 259-372.
6. BOULANGER, G. & LÜSCHER, T.F. (1990). Release of endothelin from the porcine aorta: inhibition by endothelium-derived nitric oxide. J. Clin. Invest., 85, 587-590.
7. CARRIER, M., TRONC, F., STEWART, D. & PELLETIER, L.C. (1991). Dose-dependent effect of cyclosporin on renal arterial resistance in dogs. Am. J. Physiol., 261, H1791-H1796.
8. CHIU, P.J.S., VEMULAPALLI, S., SABIN, C., RIVELLI, M., BERNARDINO, V. & SYBERTZ, E.J. (1992). Sympathoadrenal stimulation, not endothelin, plays a role in acute pressor response to cyclosporine in anesthetized rats. J. Pharmacol. Exp. Ther., 261, 994-999.
9. DAVIS, L.S., HALEEN, S.J., DOHERTY, A.M., CODY, W.L. & KEISER, J.A. (1994). Effects of selective endothelin antagonists on the hemodynamic response to cyclosporine A. J. Am. Soc. Nephrol., 4, 1448-1454.
10. DE LIMA, J.J.G., XUE, H., COBURN, L., ANDOH, T.F., MCCARRON, D.A., BENNETT, W.M. & ROULLET, J.-B. (1999). Effects of FK 506 in rat and human resistance arteries. Kid. Int., 55, 1518-1527.
11. DIEDERICH, D., SKOPEC, J., DIEDERICH, A. & DAI, F.X. (1994). Cyclosporine produces endothelial dysfunction by increased production of superoxide. Hypertension, 23, 957-961.
12. DUSTING, G.J., AKITA, K., HICKEY, H., SMITH, M. & GUREVICH, V. (1999). Cyclosporin A and tacrolimus (FK506) suppress expression of inducible nitric oxide synthase in vitro by different mechanisms. Br. J. Pharmacol., 128, 337-344.
13. EPSTEIN, A., BEALL, A., WYNN, J., MULLOY, L. & BROPHY, C.M. (1998). Cyclosporine, but not FK506, selectively induces renal and coronary artery smooth muscle contraction. Surgery, 123, 456-460.
14. GARDINER, S.M., COMPTON, A.M. & BENNETT, T. (1990a). Regional haemodynamic effects of endothelin-1 and endothelin-3 in conscious Long Evans and Brattleboro rats. Br. J. Pharmacol., 99, 107-112.
15. GARDINER, S.M., COMPTON, A.M., BENNETT, T., PALMER, R.M.J. & MONCADA, S. (1990b). Control of regional blood flow by endothelium-derived nitric oxide. Hypertension, 15, 486-492.
16. G-nitro-L-arginine methyl ester in conscious, Long Evans rats. Br. J. Pharmacol., 101, 625-631.
17. G-monomethyl-L-arginine in conscious rats. Br. J. Pharmacol., 118, 352-354.
18. GARR, M.D. & PALLER, M.S. (1990). Cyclosporine augments renal but not systemic vascular reactivity. Am. J. Physiol., 258, F211-F217.
19. 2 receptor-dependent pathway. J. Cardiovasc. Pharmacol., 36, 693-698.
20. HARRISON, S., REDDY, S., PAGE, C.P. & SPINA, D. (1998). Stimulation of airway sensory nerves by cyclosporine A and FK506 in guinea-pig isolated bronchus. Br. J. Pharmacol., 125, 1405-1412.
21. JANSSEN, P.M.L., ZEITZ, O., KEWELOH, B., SEIGEL, U., MAIER, L.S., BARCKHAUSEN, P., PIESKE, B., PRESTLE, J., LEHNART, S.E. & HASENFUSS, G. (2000). Influence of cyclosporine A on contractile function, calcium handling and energetics in isolated human and rabbit myocardium. Cardiovasc. Res., 47, 99-107.
22. KAWAI, R., MATHEW, D., TANAKA, C. & ROWLAND, M. (1998). Physiologically based pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and scale-up to human. J. Pharmacol. Exp. Ther., 287, 457-468.
23. KAYE, D., THOMPSON, J., JENNINGS, G. & ESLER, M. (1993). Cyclosporine therapy after cardiac transplantation causes hypertension and renal vasoconstriction without sympathetic activation. Circulation, 88, 1101-1109.
24. KIM, H.C., PARK, S.B., HAN, S.Y., WHANG, E.A., JEON, D.S., KIM, H.T., CHO, W.H. & PARK, C.H. (2003). Primary immunosuppression with tacrolimus in renal transplantation: a single center experience. Transplant. Proc., 35, 217-218.
25. LASSILA, M., FINCKENBERG, P., PERE, A.-K., KROGERUS, L., AHONEN, J., VAPAATALO, H. & NURMINEN, M.-L. (2000). Comparison of enalapril and valsartan in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet. Br. J. Pharmacol., 130, 1139-1347.
26. 2/prostaglandin endoperoxide receptor antagonist ifetroban. J. Pharmacol. Exp. Ther., 271, 730-734.
27. LO RUSSO, A., PASSAQUIN, A.-C., SKUTELLA, A.M. & RUEGG, U.T. (1996). Effect of cyclosporin A and analogues on cytosolic calcium and vasoconstriction: possible lack of relationship to immunosuppressive activity. Br. J. Pharmacol., 118, 885-892.
28. LYSON, T., ERMEL, L.D., BELSHAW, P.J., ALBER, D.G., SCHREIBER, S.L. & VICTOR, R.G. (1993). Cyclosporine-and FK 506-induced sympathetic activation correlates with calcineurin-mediated inhibition of T-cell signalling. Circ. Res., 73, 596-602.
29. LYSON, T., MCMULLAN, D.M., ERMEL, L.D., MORGAN, B.J. & VICTOR, R.G. (1994). Mechanism of cyclosporine-induced sympathetic activation and acute hypertension in rats. Hypertension, 23, 667-675.
30. MCKENZIE, N., DEVINENI, R., VEZINA, W., KEOWN, P. & STILLER, C. (1985). The effect of cyclosporine on organ blood flow. Transplant. Proc., 17, 1973-1975.
31. MILTING, H., JANSSEN, P.M.L., WANGENMANN, T., KOGLER, H., DOMEIER, E., SEIDLER, T., HAKIM, K., GRAPOW, M., ZEITZ, O., PRESTLE, J. & ZERKOWSKI, H.R. (2001). FK506 does not affect cardiac contractility and adrenergic response in vitro. Eur. J. Pharmacol., 430, 299-304.
32. MORGAN, B.J., LYSON, T., SCHERRER, U. & VICTOR, R.G. (1991). Cyclosporine causes sympathetically mediated elevations in arterial pressure in rats. Hypertension, 18, 458-466.
33. MOSS, N.G., POWELL, S.L. & FALK, R.J. (1985). Intravenous cyclosporine activates afferent and efferent renal nerves and causes sodium retention in innervated kidneys in rats. Proc. Natl. Acad. Sci. U.S.A., 82, 8222-8226.
34. NAIK, J.S., O'DONAUGHY, T.L. & WALKER, B.R. (2003). Endogenous carbon monoxide is an endothelial-derived vasodilator factor in the mesenteric circulation. Am. J. Physiol., 284, H838-H845.
35. ORIJI, G.K. & KEISER, H.R. (1998). Role of nitric oxide in cyclosporine A-induced hypertension. Hypertension, 32, 849-855.
36. ROULLET, J.B., XUE, H., MCCARRON, D.A., HOLCOMB, S. & BENNETT, W.M. (1994). Vascular mechanisms of cyclosporine-induced hypertension in the rat. J. Clin. Invest., 93, 2244-2250.
37. SABBATINI, M., SANSONE, G., UCCELLO, F., DE NICOLA, L., NAPPI, F. & ANDREUCCI, V.E. (2000). Acute effects of rapamycin on glomerular dynamics: a micropuncture study in the rat. Transplantation, 69, 1946-1990.
38. SANCHEZ, H., ZOLL, J., BIGARD, X., VEKSLER, V., METTAUER, B., LAMPERT, E., LONSDORFER, J. & VENTURA-CLAPIER, R. (2001). Effect of cyclosporin A and its vehicle on cardiac and skeletal muscle mitochondria: relationship to efficacy of the respiratory chain. Br. J. Pharmacol., 133, 781-788.
39. SANDER, M., LYSON, T., THOMAS, G.D. & VICTOR, R.G. (1996). Sympathetic neural mechanisms of cyclosporine-induced hypertension. Am. J. Hypertens., 9, 121S-138S.
40. STEIN, C.M., HE, H., PINCUS, T. & WOOD, A.J.J. (1995). Cyclosporine impairs vasodilation without increased sympathetic activity in humans. Hypertension, 26, 705-710.
41. STROES, E.S.G., LUSCHER, T.F., DE GROOT, F.G., KOOMANS, H.A. & RABELINK, T.J. (1997). Cyclosporin A increases nitric oxide activity in vivo. Hypertension, 29, 570-575.
42. TAKEDA, Y., MIYAMORI, I., FURUKAWA, K., INABA, S. & MABUCHI, H. (1999). Mechanisms of FK 506-induced hypertension in the rat. Hypertension, 33, 130-136.
43. TAKEDA, Y., MIYAMORI, I., WU, P., YONEDA, T., FURUKAWA, K. & TAKEDA, R. (1995). Effects of an endothelin receptor antagonist in rats with cyclosporine-induced hypertension. Hypertension, 26, 932-936.
44. TEXTOR, S.C., SMITH-POWELL, L. & TELLES, T. (1990). Altered pressor responses to NE and ANG II during cyclosporin A administration to conscious rats. Am. J. Physiol., 258, H854-H860.
45. THEODORSSON-NORHEIM, E. (1987). Friedman and Quade tests: BASIC computer program to perform non-parametric two-way analysis of variance and multiple comparisons on ranks of several related samples. Comput. Biol. Med., 17, 85-99.
46. VASQUEZ, E.M. (2000). Sirolimus, a new agent for prevention of renal allograft rejection. Am. J. Health-Syst. Pharm., 57, 437-448.
47. VISNER, G.A., LU, F., ZHOU, H., LIU, J., KAZEMFAR, K. & AGARWAL, A. (2003). Rapamycin induces heme oxygenase-1 in human pulmonary vascular cells. Circulation, 107, 911-916.
48. YARIS, E. & TUNCER, M. (1995a). The effect of indomethacin on cyclosporin A-and its solvent-induced inhibition of endothelium-dependent relaxation and the drug-induced contraction of rabbit isolated arteries. Gen. Pharmacol., 26, 93-97.
49. YARIS, E. & TUNCER, M. (1995b). Cyclosporin A and cremophor-EL augment renal vascular responses to various agonists and nerve stimulation. Arch. Int. Pharmacodyn., 329, 405-417.
50. YARIS, E., TUNCER, M. & ILHAN, M. (1992). Actions of cyclosporine A preparation and cremophor-EL in rabbit mesenteric artery and thoracic aorta in vitro. Clin. Sci., 83, 179-182.
51. YARIS, E., TUNCER, M., KAYAALP, S.O. & ILHAN, M. (1994). Direct vascular smooth muscle contractile effect of cyclosporin A and its vehicle in rabbit isolated arteries. Arch. Int. Pharmacodyn., 327, 166-174.
52. ZHANG, W. & VICTOR, R.G. (2000). Calcineurin inhibitors cause renal afferent activation in rats: a novel mechanism of cyclosporine-induced hypertension. Am. J. Hypertens., 13, 999-1004.